http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 17 Jul 2026 09:13:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+Eli+Lilly+%28LLY%29+on+Deal+to+Acquire+ATAI/26782459.html <p>UBS analyst Michael Yee reiterated a Buy rating and $1,425.00 price target on Eli Lilly (NYSE: LLY).</p><p>The analyst commented, "Eli Lilly announced it will acquire ATAI (AtaiBeckley) for ~$2.8B upfront, and up to $1B in CVR. Strategically, the acquisition aligns and actually coincides with Dave Ricks comments on an investor podcast a few weeks ago in which he believes neuropsych can be an area of development that could have the best chance of "competing with the cardiometabolic" portfolio ie because big TAM and underpenetrated markets. Today's deal gives LLY the optionality to play in this market with a Phase III http://www.streetinsider.com/Analyst+Comments/UBS+Reiterates+Buy+Rating+on+Eli+Lilly+%28LLY%29+on+Deal+to+Acquire+ATAI/26782459.html Fri, 17 Jul 2026 09:13:14 -0400 LLY http://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+AtaiBeckley+Inc+%28ATAI%29%3A+%27LLY+Acquisition+Validates+Psychedelic+Advantages%27/26777865.html <p>Oppenheimer analyst Jay Olson reiterated an Outperform rating and $16.00 price target on AtaiBeckley Inc (NASDAQ: ATAI).</p><p>The analyst comments "We view LLY's acquisition of ATAI for ~$3.8B total equity value as validating our conviction in the transformative potential of psychedelic medicine. We see unique advantages for the shorter-acting MOAs of BPL-003 (5-MeO-DMT) and VLS-01, for which we imagine operational synergies for a large pharma that could most readily leverage commercial infrastructure to accelerate uptake. Deal terms include ~$2.8B upfront reflecting a $6.75/share value plus ~$1B in CVRs including: 1) $1.00/share upon initiating a Ph3 study for VLS-01 within 4 years http://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+AtaiBeckley+Inc+%28ATAI%29%3A+%27LLY+Acquisition+Validates+Psychedelic+Advantages%27/26777865.html Thu, 16 Jul 2026 10:00:57 -0400 ATAI LLY http://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+AtaiBeckley+Inc+%28ATAI%29%3A+%27LLY+Acquisition+Validates+Psychedelic+Advantages%27/26777865.html <p>Oppenheimer analyst Jay Olson reiterated an Outperform rating and $16.00 price target on AtaiBeckley Inc (NASDAQ: ATAI).</p><p>The analyst comments "We view LLY's acquisition of ATAI for ~$3.8B total equity value as validating our conviction in the transformative potential of psychedelic medicine. We see unique advantages for the shorter-acting MOAs of BPL-003 (5-MeO-DMT) and VLS-01, for which we imagine operational synergies for a large pharma that could most readily leverage commercial infrastructure to accelerate uptake. Deal terms include ~$2.8B upfront reflecting a $6.75/share value plus ~$1B in CVRs including: 1) $1.00/share upon initiating a Ph3 study for VLS-01 within 4 years http://www.streetinsider.com/Analyst+Comments/Oppenheimer+on+AtaiBeckley+Inc+%28ATAI%29%3A+%27LLY+Acquisition+Validates+Psychedelic+Advantages%27/26777865.html Thu, 16 Jul 2026 10:00:57 -0400 ATAI LLY http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html <p>Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing treatments for mental health conditions, in a deal valued at up to approximately $3.8 billion.</p> <p>Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of approximately $2.8 billion. AtaiBeckley shareholders will also receive a Contingent Value Right (CVR) worth up to $2.50 per share in additional cash payments tied to development and regulatory milestones for AtaiBeckley's two lead programs, representing a potential additional aggregate equity value of approximately $1.0 billion. http://www.streetinsider.com/Mergers+and+Acquisitions/Eli+Lilly+to+acquire+AtaiBeckley+for+up+to+%243.8B/26776271.html Thu, 16 Jul 2026 06:45:23 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819 http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html <div class="xn-content"> <p class="prntac"><i>AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression </i></p><p class="prntac"><i>Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health </i></p><p><span class="legendSpanClass"><location value="LU/us.in.indpol" idsrc="xmltag.org" >INDIANAPOLIS</location> and <location value="LU/us.ny.nyc" idsrc="xmltag.org" >NEW YORK</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:LLY" idsrc="xmltag.org" >Eli Lilly and Company</span> (NYSE: LLY) and <span value="ACORN:5021668354" idsrc="xmltag.org" >AtaiBeckley Inc.</span> (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley.</p><p>AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a http://www.streetinsider.com/Press+Releases/Lilly+to+acquire+AtaiBeckley+to+advance+therapies+for+treatment-resistant+depression+and+other+mental+health+conditions/26776267.html Thu, 16 Jul 2026 06:45:00 -0400 A.02846591 A.05453562 A.05786303 A.06822034 A.40540380 A.50216683 ATAI LLY O.00046809 O.00981936 O.03044482 O.20026344 O.21355689 O.48309657 O.50752819